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Abstract
Background: Little is known about the plasma levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), and the
relationship between the severity of coronary heart disease (CHD) with NT-proBNP and multiple biomarkers in diabetic and
pre-diabetic patients, compared to individuals with normal glucose levels.
Methods: Four hundred and fifteen consecutive Chinese patients of both sexes were assigned to three groups on the basis
of the new hemoglobin (Hb) A1c (HbA1c) cut-off points for diagnosis of diabetes and pre-diabetes. The three groups were
divided into tertiles according to NT-proBNP, hs-CRP, cystatin C, and troponin T levels. Gensini scores were compared
among the three groups and biomarker tertiles. Receiver operating characteristic (ROC) curves were used to obtain the
angiographic CHD cut-off points for each biomarker. Stepwise multivariate linear correlation analysis was applied to
examine the association between the severity of CHD and biomarker levels.
Results: Gensini scores increased with increasing biomarker tertile levels and HbA1c. Gensini scores were significantly
different in the middle and upper NT-proBNP tertiles of the diabetic, pre-diabetic and control groups. NT-proBNP had the
highest positive and negative predictive values and area under the curve for CHD. Only NT-proBNP was identified as an
independent variable for Gensini score.
Conclusions: Plasma NT-proBNP may be an important biomarker to evaluate the severity of CHD and screen for CHD in
diabetic or pre-diabetic patients.
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Introduction
Coronary heart disease (CHD) is the main cause of morbidity
and mortality in developed countries, and the prevalence is
increasing in developing countries. In China, nearly two thirds of
chronic heart failure is the result of CHD [1]. Several studies have
reported biomarker clusters which are associated with CHD. The
assessment of these biomarkers, alone or in combination, may
improve the long-term prediction of mortality or first major
cardiovascular event compared to conventional risk markers [2,3].
N-terminal pro-brain natriuretic peptide (NT-proBNP) was
identified as a novel and important CHD biomarker, and has
prognostic value in patients with stable CHD [4]. A report from
the BELSTRESS study suggested that NT-proBNP levels were a
strong predictor of coronary events in over 10,000 working men
after 2.66 years, even after adjustment for conventional risk factors
[5]. However, recently two studies reported that NT-proBNP was
not more predictive of long-term CVD and CVD outcomes in
individuals without pre-existing CHD than conventional risk
factors [6,7]. This suggests that NT-proBNP may be more suitable
for screening individuals with preexisting CHD.
Inflammation plays a role in the pathogenesis of CHD, and
cystatin C and high-sensitive C-reactive protein (hs-CRP) may act
as markers of inflammation [8,9]. cystatin C is a newer biomarker
associated with ischemia independent of kidney function, and may
contribute to atherosclerotic plaque vulnerability [8]. Hs-CRP is
one of the most studied non-traditional biomarkers for the
evaluation of CHD risk [10,11].
Diabetes is an established risk factor for CHD [12]; however, it
remains unknown whether plasma BNP levels and other
biomarkers are increased in diabetic and pre-diabetic patients
with coronary artery stenosis. In this study, we aimed to determine
whether plasma levels of NT-proBNP and other biomarkers
altered with changes in the severity of CHD, and whether these
markers are appropriate for rapidly identifying symptomatic or
asymptomatic CHD in diabetic or pre-diabetic Chinese patients.
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Ethics statement
The present study was approved by the Ethics Committee of the
Huashan Hospital, Shanghai, China. Verbal informed consent
was obtained from all patients. The study was a cross-sectional
study performed in inpatients.
Patients
Four hundred and fifteen consecutive symptomatic or non-
symptomatic Chinese patients scheduled for coronary angiography
for suspected myocardial ischemia were recruited between
February 2008 and March 2009 at the Huashan Hospital of
Fudan University, China. Patients with valvular disease, dilated or
hypertrophic cardiomyopathy, hyperthyroidism and hypothyroid-
ism were excluded from the study to eliminate potential
confounding factors which may influence heart function and
plasma biomarkers. The patients were divided into diabetic
(including previous history of diabetes), pre-diabetic, and control
groups according to the new HbA1c cut-off points for diagnosis of
diabetes or pre-diabetes [13]. A fasting venous blood sample was
obtained for measurement of fasting glucose and HbA1c. Patients
with HbA1c levels $5.7% to 6.4% were considered pre-diabetic;
patients with HbA1c levels $6.5% were diagnosed as diabetic,
even without previous history of diabetes. In each group, the
subjects were subdivided into tertiles based on plasma levels of
NT-proBNP, troponin T, hs-CRP and cystatin C. Subjects were
interviewed for medical history (e.g., hypertension and diabetes)
and smoking habits. Body weight and height were measured to
determine the body mass index (BMI; BMI, kg/m
2=weight (kg)/
[height (m)]
2). Blood pressure was measured by standard methods.
Laboratory assays
Venous blood was collected after overnight fasting before
coronary artery angiography. Fasting plasma glucose (FPG) was
quantified by the glucose oxidase procedure; HbA1c was measured
by ion-exchange high-performance liquid chromatography (HPLC;
Bio-Rad, Hercules, CA, USA). The homeostasis model assessment
insulin resistance estimate (HOMA-IR) was calculated as serum
glucose (mg/dL)6plasma insulin (mU/mL)/22.5, serum total
cholesterol (TC), high-density lipoprotein (HDL) cholesterol,
triglyceride (TG) levels, apolipoprotein A1 (apo-AI) and B (apo-B),
lipoprotein (a) (LP(a)), creatinine (Cr), and uric acid (UA) were
measured by an enzymatic method with a chemical analyzer
(Hitachi 7600-020, Tokyo, Japan). Low-density lipoprotein (LDL)
cholesterol was calculated using the Friedewald formula, and
creatinine clearance rate (Ccr) was calculated using the Cockcroft-
Gault formula. An enzyme coupled method was used to measure
urine creatinine concentration and to calculate the urinary
albumin/urinary creatinine ratio (Alb/Cr). The electrochemilumi-
nescence-based immunoanalytical system, Elecsys 2010 (Roche
Diagnostics Ltd., Mannheim, Germany) was used to determine
plasma levels of NT-proBNP, plasma insulin, C peptide, and
urinary albumin. Immunoturbidimetry was used to determine
serum cystatin C, hs-CRP, and troponin I. The day-to-day and
inter-assay coefficients of variation at the central laboratory in our
hospital for all analyses were between 1% and 3%.
Echocardiography
Two-dimensional and Doppler echocardiography scans were
performed using the HP77020A echocardiograph (Hewlett Pack-
ard Company, USA). The aortic dimension (AOD), left atrial
dimension (LAD), interventricular septal thickness (IVST), poste-
rior wall thickness (PWT), left ventricular end-diastolic diameter
(LVEDd) and ejection fraction (EF) percentage were assessed. The
left ventricular mass index (LVMI) was calculated using the
Devereux equation. LVM (g) was calculated using 1.046[(IVSTd+
LVPWTd+LVEDd)
32(LVEDd)
3]213.6. Body surface area (BSA,
m
2) was calculated using 0.00616height (m)+0.01286body weight
(kg)20.1529; LVMI (g /m
2)=LVM/BSA.
Angiographic assessments
A catheterizing cardiologist and qualified and experienced
angiographer performed the angiographic assessments, while
blinded to the patient biomarker levels. Coronary angiography
was performed the Judkins technique. Angiographic coronary
artery disease (CAD) was defined as a stenotic lesion of at least
50% in one or more major coronary arteries or the main coronary
artery. The severity of angiographic CHD was quantified precisely
using the Gensini score [14].
Statistical analysis
Data were expressed as mean 6 SD for continuous variables, or
as percentages for categorical variables. Statistical analysis was
performed using SPSS for Windows (Version 13.0). NT-proBNP
and Alb/Cr values were logarithmically transformed as they were
not normally distributed. Age, sex, and smoking were adjusted by
covariance analysis. Repeated measures one-way ANOVA was
used to determine the significance of trends within groups.
Numerical data was compared using the chi-square test. Receiver
operating characteristic (ROC) curves and Youden indexes were
used to obtain the biomarker cut-off points for predicting the
prevalence of angiographic CHD. The respective areas under the
curve (AUC), sensitivity, specificity, positive predictive value, and
negative predictive value were compared among biomarkers, and
in total. Stepwise multivariate linear correlation analysis was
applied to examine the association between the severity of CHD,
test factors and each biomarker.
Results
Demographic and metabolic characteristics of subjects
Of the 415 patients, age, hypertension, BMI, SBP, HOMA-IR,
Loge alb/Cr, LVMI and Gensini score were significantly different
between groups and rose progressively from control group,
pre-diabetes group,diabetes group (Table 1). HDL cholesterol
level decreased gradually in the three groups. The percentage of
patients with previous CHD, confirmed by cardiac angiography or
known myocardial infarction within the past 6 years, and the type
of anti-hypertensive treatment or anti-lipid treatment did not
differ significantly among the control, pre-diabetic and diabetic
groups.
Comparison of NT-proBNP, troponin T, hs-CRP, and
cystatin C with the severity of CHD in the control,
pre-diabetic, and diabetic patients
There was a progressive and graded relationship between
Gensini score and NT-proBNP, hs-CRP and cystatin C tertiles
from the control to the pre-diabetic and diabetic group (Fig. 1 A–
C). The differences in Gensini score were significant among the
tertiles of all groups; The differences in troponin T among patient
groups were significant; however, the differences in the tertile
subgroups were not significant. The Gensini score among the
diabetic, pre-diabetic and control groups in the second and third
tertiles was significantly related to NT-proBNP levels, and these
differences remained significant after covariance analysis adjust-
ment for age, sex, and smoking habits.
NT-proBNP and Severity of Coronary Artery Disease
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cystatin C for angiographic CHD
The respective cut-off points for diagnosis of CHD were
estimated according to the ROC curves and the Youden indexes
for NT-proBNP, troponin T, hs-CRP, and cystatin C (Fig. 2).
Using these cut-off points, NT-proBNP showed higher sensitivity,
specificity, positive and negative predictive values with a greater
area under the ROC curve than other biomarkers, except for the
specificity and positive predictive value of troponin T. By com-
bining the four biomarkers we obtained a slightly greater area
under the ROC curve and higher positive predictive value for
CHD, using the ROC curves and Youden index, (Table 2).
Correlation of NT-proBNP and multiple biomarkers with
severity of angiographic CAD in diabetic, pre-diabetic
and control groups
The correlation of NT-proBNP and multiple biomarkers with
angiographic CAD in the diabetic and pre-diabetic groups was
obtained through linear stepwise regression analysis (See Table
S1). In the diabetic, pre-diabetic and control groups, as well as the
total study population, NT-proBNP manifested as significant
variable which contributed to the Gensini score. All other bio-
markers, including troponin T, hs-CRP, and cystatin C, were not
identified as independent variables. Other independent variables
contributing to Gensini score were age, BMI, HOMA-IR, TC,
HDL, apo-AI, LP(a), Cr, Ccr (%), EF, and LVMI, in different
combinations.
Discussion
In this study, in which the new HbA1c criteria were applied for
the diagnosis of pre-diabetes and diabetes, we observed a
progressive and graded relationship between NT-proBNP, tropo-
nin T, hs-CRP and cystatin C tertile levels and the severity of
angiographic CHD in high-risk patients. The severity of angio-
graphic CHD was increased in diabetic and pre-diabetic patients
in the middle and upper NT-proBNP tertiles. To our knowledge,
only few similar studies have been conducted, and this is the first
report in a Chinese population.
Table 1. Characteristics of the control, pre-diabetic and diabetic study groups.
Groups Control (n=137) Pre-diabetes(n=149) Diabetes(n=129) P-value
Age (Mean year 6 SD) 65.01611.23 67.60610.89 69.09610.34 0.008
Males % (n) 59.9 (82/137) 65.1 (97/149) 60.5 (78/129) .0.05
Current smokers % (n) 25.6 (35/137) 26.8 (40/149) 25.6 (33/129) .0.05
Hypertension % (n) 64.9 (89/137) 68.5 (102/149) 81.4 (105/129) ,0.01
BMI (Mean kg/m
2 6 SD) 24.2463.50 24.5463.55 25.4763.55 0.013
SBP (Mean mmHg 6 SD) 130.96617.18 130.75618.75 137.62619.73 0.003
DBP (Mean mmHg 6 SD) 77.70610.78 76.55610.30 78.0661.40 0.509
FPG (Mean mmol/L6 SD) 5.0360.68 5.4560.81 7.3562.54 0.000
HbAlc (Mean % 6 SD) 5.3760.23 5.95460.20 7.2861.27 0.000
HOMA-IR (Mean % 6 SD) 2.5161.63 2.8761.97 4.7464.19 0.000
Fasting insulin (Mean mg/L 6 SD) 10.6766.88 11.5767.88 13.2768.24 0.050
Fasting C peptide (Mean ng/L 6 SD) 2.0361.096 2.1461.06 2.3061.64 0.329
TC (Mean mmol/L6 SD) 4.3761.017 4.5561.00 4.5561.20 0.287
TG (Mean mmol/L6 SD) 1.5660.86 1.7461.44 1.9261.17 0.061
HDL (Mean mmol/L6 SD) 1.1260.29 1.1160.24 1.0460.26 0.029
LDL (Mean mmol/L6 SD) 2.6560.93 2.7560.86 2.7561.01 0.609
APO-AI (Mean ng/L 6 SD) 1.0260.16 1.0260.15 0.9960.16 0.275
APO-B(Mean ng/L 6 SD) 0.7460.23 0.8060.23 0.8060.26 0.135
LP(a) (Mean ng/L 6 SD) 160.176136.35 200.396163.61 175.746158.16 0.079
Loge alb/Cr (Mean 6 SD) 2.1060.77 2.4161.24 2.9561.54 0.000
BUN (Mean mmol/L6 SD) 5.8061.86 6.1061.67 6.1562.04 0.251
Cr (Mean mmol/L6 SD) 77.96618.18 78.56617.71 80.29626.36 0.646
Ccr (Mean % 6 SD) 77.48626.57 76.06626.06 76.25630.27 0.903
UA (Mean mmol/L 6 SD) 0.3460.10 0.3660.10 0.3360.08 0.075
Heart rate (Mean bmp 6 SD) 72.09610.06 71.12610.11 73.33610.75 0.253
EF (Mean % 6 SD) 64.7069.51 63.04610.38 62.15611.29 0.130
LVMI(Mean kg/m
2 6 SD) 119.12635.10 125.74649.80 134.46636.14 0.011
Gensini score (Mean 6 SD) 22.67636.10 25.94632.96 33.63636.57 0.043
Previous CHD % (N) 11.7 (16/137) 14.1 (21/149) 14.7 (19/129) .0.05
Anti-hypertension treatment % (N) 29.9 (41/137) 30.9 (46/149) 40.3 (52/129) .0.05
Anti-lipids treatment % (N) 40.2 (55/137) 49.0 (73/149) 55.8 (72/129) .0.05
doi:10.1371/journal.pone.0022563.t001
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increased left ventricular wall stress, in the absence of cardiac
ischemia, thus, NT-pro-BNP can reflect heart function and heart
hypertrophy, as well being closely related to CHD [15].
Furthermore, NT-proBNP concentrations increased proportion-
ally to the size of myocardial infarct estimated using scintigraphy,
despite the absence of heart failure in asymptomatic myocardial
infarct patients [16]. Elevated BNP may be associated with a
greater severity and degree of myocardial ischemia, and may
partly explain the association between elevated BNP levels and
adverse outcomes [17]. Several studies have revealed that NT-
proBNP levels reflect the extent of ischemia in patients with stable
CAD accompanied by episodes of ischemia [18] and patients with
exercise-induced myocardial ischemia [19]. Our findings are in
agreement with the results of several previous studies [18,19]
where NT-proBNP plasma levels were closely related to the
severity of angiographic CHD. Furthermore, in our study, the
mean levels of NT-proBNP in the middle and top tertiles were
greater than the cut-off point (78.9 pg/mL) for diagnosis of
angiographic CHD (Table 2), indicating the severity of CHD
increased gradually in tertile groups, as well as from the control to
the pre-diabetic and diabetic groups.
In recent years, the ability of troponin I, cystatin C, and hs-CRP
to predict risk of death or cardiovascular events has been evaluated
in addition to NT-proBNP [3]. Hs-CRP is one of the most studied
non-traditional biomarkers for the CHD risk. One study rigorously
evaluated the predictive utility of other novel risk markers such as
CRP, excluding NT-proBNP, and indicated that they offer
minimal improvement over the Framingham Risk Score [20];
however, another suggested that hs-CRP, combined with NT-
proBNP, troponin I, and cystatin C, is associated with CHD when
the influence of age is excluded, and in niche populations [21]. It
has been recognized that hs-CRP and cystatin C are markers of
inflammation and that cystatin C is associated with ischemia. Our
study found that hs-CRP and cystatin C are related to Gensini
score; however, the AUC, positive predictive value, and negative
predictive value of hs-CRP and cystatin C were lower than NT-
proBNP. Furthermore, unlike NT-proBNP, the biomarkers hs-
CRP, cystatin C, and troponin T were not identified as
independent variables in stepwise linear models to assess the
relationship with existing CHD. This finding suggests hs-CRP,
cystatin C, and troponin T have a weak or indirect relationship
with the severity of coronary arterial stenosis in the control, pre-
diabetes, or diabetes groups. Troponin I, similar to troponin T in
structure and clinical significance, indicates myocardial necrosis
and is an established ‘‘gold standard’’ for diagnosis of myocardial
infarction, explaining the high specificity and positive predictive
value of Troponin T for diagnosis of CHD. We hypothesis that
Troponin T may not increase proportionally with Gensini score as
the severity of necrosis is not equal to the severity of coronary
arterial stenosis.
Our results also revealed moderate efficacy (and no improve-
ment) in sensitivity and specificity using a single biomarker, such as
NT-proBNP, to screen or diagnose angiographic CHD. Although
coronary angiography is considered the gold standard for
evaluation of the degree of coronary stenosis, some researchers
Figure 2. Receiver operating characteristic curves to predict angiographic coronary heart disease in hospitalized high-risk Chinese
patients. ROC curves show NT-proBNP, troponin T, hs-CRP and cystatin C for the prediction of angiographic coronary heart disease (CHD) in
hospitalized high-risk Chinese patients.
doi:10.1371/journal.pone.0022563.g002
Figure 1. Gensini scores were compared among the three groups and biomarker tertiles. Scores were calculated according to (A) NT-
proBNP, (B) hs-CRP (C) cystatin C and (D) troponin T tertiles in the control, pre-DM and DM groups. Pre-DM: pre-diabetes, DM: diabetes mellitus.
doi:10.1371/journal.pone.0022563.g001
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tomography angiography (CTA) or intravascular ultrasound. As
these techniques allow visualization of atherosclerosis, they are
particularly valuable for accurate early identification of CAD [22].
We assume that the sensitivity and even specificity of NT-proBNP
may correlate better with CTA and intravascular ultrasound
results than coronary artery angiography findings.
It is well known that glucose level is directly linked to CVD risk.
The Reykjavik Study and a meta-analysis suggested a slightly
stronger association between CHD risk and HbA1c levels than
fasting or post-load glucose levels [23]. A prospective observational
study (UKPDS-35) revealed that every 1% reduction in baseline
HbA1c levels decreases the incidence of myocardial infarction by
5% [24]. In 2010, the American Diabetes Association (ADA)
formally recommended new HbA1c criteria for the diagnosis of
diabetes and pre-diabetes [15], and these criteria were used in our
study. Additionally, as symptomatic hospitalized patients experi-
ence physiological and psychological stress, which may increase
blood glucose levels, use of HbA1c levels categorize hyperglycemia
in our study was reasonable. Progressive narrowing of the
coronary arteries was observed in all 3 groups, from individuals
with HbA1c levels ,5.7%, to pre-diabetes at 5.7–6.4%, and
diabetics with HbA1c $6.5%. This observation is in agreement
with the findings of numerous studies, including a previous study
by our group [25], where the increase in CHD was investigated
pre-diabetic and diabetic individuals using glucose levels. As a
marker of CHD, NT-proBNP showed the same trend which
increased with regard to the severity or prevalence of CHD.
In summary, we demonstrated that plasma NT-proBNP levels
are closely related to the severity of CHD in a Chinese population
of diabetic and pre-diabetic patients. The relationship between
NT-proBNP and CHD was stronger in diabetic and pre-diabetic
patients than normoglycemic controls. NT-proBNP is a stronger
predictor of CHD than other biomarkers such as troponin T, hs-
CRP, and cystatin C, which have been suggested to be predictors
of CHD risk. As a diagnostic tool, plasma NT-proBNP levels may
not be sensitive and specific enough; therefore, further studies are
needed to determine the potential of NT-proBNP as a biomarker
of CHD.
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